Show simple item record

dc.contributor.authorDriessen, CMLen_US
dc.contributor.authorGroenewoud, JMMen_US
dc.contributor.authorde Boer, JPen_US
dc.contributor.authorGelderblom, Hen_US
dc.contributor.authorvan der Graaf, WTAen_US
dc.contributor.authorPrins, JBen_US
dc.contributor.authorKaanders, JHAMen_US
dc.contributor.authorvan Herpen, CMLen_US
dc.coverage.spatialGermanyen_US
dc.date.accessioned2019-02-25T16:32:00Z
dc.date.issued2018-04en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29230548en_US
dc.identifier10.1007/s00520-017-3946-7en_US
dc.identifier.citationSupport Care Cancer, 2018, 26 (4), pp. 1233 - 1242en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3093
dc.identifier.eissn1433-7339en_US
dc.identifier.doi10.1007/s00520-017-3946-7en_US
dc.description.abstractPURPOSE: The CONDOR study showed that docetaxel/cisplatin/5-fluorouracil (TPF) followed by conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 (cis100 + RT; n = 27)) versus accelerated radiotherapy with cisplatin weekly 40 mg/m2 (cis40 + ART; n = 29) in locally advanced head and neck cancer (LAHNC) patients was not feasible. Here, we report the analysis of health-related quality of life (HRQOL) of the patients entered in this study. METHODS: HRQOL was assessed at baseline, after two TPF, before start of chemoradiotherapy, and 1, 4, 8, 12, and 24 months after completion of chemoradiotherapy using the EORTC-QLQ-C30 and QLQ-H&N35 in 62 patients. RESULTS: Compliance with the QOL questionnaires was 94% (59/62) at baseline and 61% (30/49) at 12 months, respectively. HRQOL decreased after TPF and further decreased during chemoradiohteray in both arms equally. Pain and swallowing dysfunction improved significantly during TPF but deteriorated below baseline levels during chemoradiotherapy, cis40 + ART > cis100 + RT (p < 0.05). HRQOL and symptoms restored to baseline within 12 months in both arms and remained at that level until 24 months. CONCLUSIONS: After TPF, cis40 + ART had a larger negative impact on symptoms than cis100 + RT, probably due to the ART. HRQOL and symptoms restored to baseline levels within 12 months after end of treatment in both arms, which is an important perspective for patients during the phase of most serious acute side effects of treatment. TRIAL REGISTRATION: NCT00774319.en_US
dc.format.extent1233 - 1242en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectChemoradiotherapyen_US
dc.subjectInduction chemotherapyen_US
dc.subjectLocally advanced head and neck canceren_US
dc.subjectQuality of lifeen_US
dc.subjectSymptomsen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectChemoradiotherapyen_US
dc.subjectCisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectFeasibility Studiesen_US
dc.subjectFemaleen_US
dc.subjectFluorouracilen_US
dc.subjectHead and Neck Neoplasmsen_US
dc.subjectHumansen_US
dc.subjectInduction Chemotherapyen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectQuality of Lifeen_US
dc.titleQuality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-10-23en_US
rioxxterms.versionofrecord10.1007/s00520-017-3946-7en_US
rioxxterms.licenseref.startdate2018-04en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfSupport Care Canceren_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublisheden_US
pubs.volume26en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical and Translational Sarcomaen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/